BABH study: a double-blind, randomized national phase 3 study to evaluate efficacy and safety of bevacizumab for the treatment of severe bleedings in hemorrhagic hereditary telangiectasia (HHT)S. Dupuis-Girod,J. Saurin, P. Philouze,E. Decullier, S. RiviOre,C. Cartier,R. Altwegg, B. Gilbert-Dussardier,P. Y. Hatron,S. Mohamed,P. Duffau,R. Corre,V Leguy-Seguin,T. Chinet,P. Lacombe,G. Lesur, J. Lesniak, J. R. HarlO,M. F. Carette,C. Lavigne, L. Laccourreye, F. Oberti, V Grobost, P. Magro, L. Alric, M. Pistorius,S. El Chehadeh, A. Fargeton,C. Pivot, G. Paintaud,F. FaureANGIOGENESIS（2018）引用 0|浏览14暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
